Health Economics›Marginal zone lymphoma›First-line therapy randomized data

First-line therapy randomized data

Marginal zone lymphoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~39.6 mo	—	~8	~R 270 994 PFS proxy · indirect	18
R-CHOP Variant #08	—	R 26 946	21d	~44.4 mo	—	~3	~R 80 838 PFS proxy · indirect	4
R-CVP Variant #01	—	R 26 502	21d	—	—	~3	~R 79 505 PFS proxy · indirect	1
Fludarabine monotherapy Variant #05	—	R 13 754	28d	—	—	8	R 110 032 PFS proxy	1
Chlorambucil monotherapy Variant #03	—	R 2 355	28d	—	69.5 mo	13	R 30 610 PFS proxy	1
Rituximab monotherapy Variant #09 Partial	—	—	28d	~20.3 mo	—	~1	—	17

7 of 7 regimens shown